Skip to main content

Table 1 Patient characteristics

From: Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma

Variables No. of patients (%)
Sex
 Male 97 (81.5)
 Female 22 (18.5)
Age (years)
 Median (range) 60 (36–90)
ECOG performance status
 0 102 (85.7)
 1 13 (10.9)
 2 4 (3.4)
Child-Pugh class
 A 108 (90.8)
 B 11 (9.2)
Viral aetiology
 Hepatitis B virus 93 (78.2)
 Hepatitis C virus 11 (9.2)
 Non B, Non C 15 (12.6)
Tumor size (cm)a
 Median 1.7
 0.8–1.0 8 (5.8)
 1.1–2.0 90 (64.7)
 2.1–3.0 32 (23.0)
 3.1–4.0 8 (5.8)
 5.1–6.0 1 (0.7)
Modified UICC stageb
 I 60 (50.4)
 II 53 (44.5)
 III 6 (5.0)
Alpha-fetoprotein (ng/mL)
 Range 1.6–4303.6
PIVKA-II (mAU/mL)
 Range 0–11,501.0
No. of prior treatment before SBRT
 Median (Range) 3 (0–25)
Summary of prior treatments
 None 3 (2.5)
 TACE 57 (47.9)
 TACE, RFA 27 (22.7)
 TACE, PEI 3 (2.5)
 TACE, RFA, PEI 1 (0.8)
 TACE, sorafenib 1 (0.8)
 Resection 2 (1.7)
 Resection, TACE 15 (12.6)
 Resection, TACE, RFA 5 (4.2)
 Resection, TACE, PEI 2 (1.7)
 Resection, RFA 2 (1.7)
 PEI 1 (0.8)
  1. ECOG Eastern Cooperative Oncology Group, UICC Union for International Cancer Control, PIVKA-II prothrombin induced by vitamin K absence-II, SBRT stereotactic body radiation therapy, TACE transarterial chemoembolization, RFA radiofrequency ablation, PEI percutaneous ethanol injection
  2. aOne hundred and thirty-nine tumors were analysed for size
  3. bModified UICC stage was assessed by the viable tumor at the timing of SBRT